Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
This study has been terminated.
( In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, the companion trial, OSI-774-206 has been stopped )
Study NCT01247922
Information provided by Astellas Pharma Inc
First Received on November 23, 2010.
Last Updated on December 11, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
